Compare DERM & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | PMN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 115.5M |
| IPO Year | 2021 | 2022 |
| Metric | DERM | PMN |
|---|---|---|
| Price | $6.00 | $9.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $12.67 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 266.2K | 20.2K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $0.29 |
| 52 Week High | $9.56 | $27.40 |
| Indicator | DERM | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 41.60 |
| Support Level | $5.77 | $9.31 |
| Resistance Level | $6.59 | $11.37 |
| Average True Range (ATR) | 0.31 | 0.64 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 33.33 | 34.51 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.